title: Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study.
abstract: BACKGROUND
  Indications for chemotherapy in gestational trophoblastic disease include raised human chorionic gonadotropin (hCG) concentrations 6 months after uterine evacuation of hydatidiform mole, even when values are falling. We aimed to establish whether chemotherapy is always necessary in these patients.
  
  
  METHODS
  We retrospectively identified women registered between January, 1993, and May, 2008, at Charing Cross Hospital, London, UK, who had persistently high hCG concentrations 6 months after evacuation of hydatidiform mole. Rates of hCG normalisation, relapse, and death were assessed in patients continued under surveillance and those who received chemotherapy after 6 months. We postulated that a surveillance policy would be clinically acceptable if hCG values returned to normal in 75% of patients or more.
  
  
  RESULTS
  76 (<1%) of 13,960 patients with hydatidiform moles had persistently high hCG concentrations of more than 5 IU/L 6 months after evacuation. 66 (87%) patients continued under surveillance and hCG values spontaneously returned to normal without chemotherapy in 65 (98%) of these patients. Values in one patient did not become normal because of chronic renal failure, but she remains healthy. Ten patients received chemotherapy, and hCG concentrations returned to normal in eight (80%) of these individuals (surveillance vs chemotherapy groups p=0·044) and remained slightly high (6-11 IU/L) in two without any associated clinical problems off treatment. We noted no significant differences between individuals in the surveillance and chemotherapy groups, apart from lower median hCG concentrations 6 months after evacuation in those under surveillance than in those given chemotherapy (13 IU/L, range 5-887, vs 157 IU/L, range 6-6438; p=0·004). Overall, there were no deaths in this series.
  
  
  CONCLUSIONS
  A surveillance policy seems to be clinically acceptable in patients with low and declining concentrations of hCG 6 months after evacuation of hydatidiform mole.
  
  
  BACKGROUND
  National Commissioning Group, Imperial Experimental Cancer Medicine Centre, Imperial Biomedical Research Centre, and Cancer Research UK.
authors: Imperial College London, London, UK.
authors: Roshan
authors: R
authors: Agarwal
authors: Suliana
authors: S
authors: Teoh
authors: Delia
authors: D
authors: Short
authors: Richard
authors: R
authors: Harvey
authors: Philip M
authors: PM
authors: Savage
authors: Michael J
authors: MJ
authors: Seckl
mesh_terms: D000293:Adolescent; D000328:Adult; D006063:Chorionic Gonadotropin / Q000032:analysis*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D006828:Hydatidiform Mole / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery*; D008875:Middle Aged; D011247:Pregnancy; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D006063:Chorionic Gonadotropin